Quantum Cyber N.V. current report, Q2 FY2025

Business Context and Reporting Period

This Form 6-K filing by Mainz Biomed N.V. (referred to in metadata as Quantum Cyber N.V.) covers the month of May 2025, specifically reporting on a material agreement entered into on May 19, 2025, with a closing date of May 21, 2025.

Key Financial Metrics and Transaction Details

The company executed a Securities Purchase Agreement (SPA) to raise capital through an Offering. Key financial terms include:

  • Gross Proceeds: Approximately $4,000,000 before deducting placement agent fees and offering expenses.
  • Offering Structure:
    • 375,000 ordinary units sold at $2.00 per unit.
    • 1,625,000 pre-funded units sold at $2.00 per unit less a nominal exercise price of $0.0001.
  • Placement Fees: 7% of gross proceeds plus a fixed fee of $85,000 paid to Maxim Group, LLC.
  • Warrant Terms:
    • Class A Warrants: Exercise price $2.00; expire 5 years from issuance.
    • Class B Warrants: Exercise price $2.00; expire 30 days after eAArly Detect2 study results or 1 year from issuance (whichever is earlier).

The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.

Material Changes and Agreements

Significant changes include the execution of the new Offering and a concurrent Warrant Amendment:

  • Warrant Price Reduction: As consideration for the new Offering, the exercise price of existing warrants from a December 2024 transaction (originally $5.85) was reduced to $2.00 per share.
  • Capital Structure Impact: The issuance of ordinary units and pre-funded units increases the number of shares outstanding upon exercise.

Outlook, Risks, and Management Commentary

Management commentary is limited to the description of the transaction mechanics. Key contingencies and risks identified include:

  • Study-Dependent Expiration: Class B Warrants have an expiration date tied to the receipt of results from the "eAArly Detect2 study," introducing uncertainty regarding the duration of these instruments.
  • Dilution: The Offering includes anti-dilution provisions for stock dividends and splits, but the immediate issuance of units and warrants will dilute existing shareholders.
  • Transaction Costs: Net proceeds will be reduced by the 7% placement fee and the $85,000 fixed fee.

Investor Verification Checklist

  • Verify the final closing date and actual net proceeds after deducting the 7% placement fee and $85,000 fixed fee.
  • Confirm the timeline for the "eAArly Detect2 study" results to determine the exact expiration date of the Class B Warrants.
  • Review the impact of the warrant price reduction on the December 2024 investors and the total potential dilution from both the new and amended warrants.
  • Check the Registration Statement on Form F-1 (no. 333-287249) for the full text of the SPA and Warrant Agreement.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.